MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
7.88
+0.02
+0.25%
After Hours: 7.88 0 0.00% 16:10 07/01 EDT
OPEN
7.96
PREV CLOSE
7.86
HIGH
8.10
LOW
7.55
VOLUME
446.01K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
3.530
MARKET CAP
203.32M
P/E (TTM)
-2.1488
1D
5D
1M
3M
1Y
5Y
1D
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B
TipRanks · 12h ago
Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026
Benzinga · 12h ago
PRECISION BIOSCIENCES - INITIAL SAFETY DATA FROM FUNCTION-DMD TRIAL TARGETED FOR YEAR-END 2026 - SEC FILING
Reuters · 13h ago
Precision BioSciences posts updated corporate presentation deck on investor website
PUBT · 13h ago
Precision BioSciences announces addition to the Russell 2000 Index
TipRanks · 2d ago
PRECISION BIOSCIENCES ANNOUNCES INCLUSION IN THE RUSSELL 2000® INDEX EXPANDING MARKET VISIBILITY WITH INSTITUTIONAL INVESTORS
Reuters · 2d ago
Weekly Report: what happened at DTIL last week (0622-0626)?
Weekly Report · 2d ago
Weekly Report: what happened at DTIL last week (0615-0619)?
Weekly Report · 06/22 09:54
More
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.